ARS Pharma terminates Recordati license for neffy in EU/UK/MEA; reacquires rights for €3M upfront plus milestones

ARS Pharmaceuticals, Inc.

Terminated License and Supply Agreement with Recordati Ireland, effective immediately.
Reacquired exclusive rights to neffy (epinephrine) for EU, UK, Middle East, Africa, Eurasia.
Pays €3.0M upfront; Recordati eligible for up to €2.0M EMA milestone, €5.0M first commercial sale, up to €5.0M sales milestones.
Total potential milestone payments to Recordati up to €12.0M.
ARS regains control of development, manufacturing, regulatory, and commercialization in the territory.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ARS Pharmaceuticals, Inc. entered into Termination Agreement with Recordati Ireland, LTD. valued at €3.0 million (effective 2023-02-22).

Action: entry
Agreement: supply
Counterparty: Recordati Ireland, LTD.
Value: €3.0 million
Effective: 2023-02-22

Exact text from the filing

On February 22, 2023, ARS Pharmaceuticals, Inc. (the “Company”) entered into a Termination Agreement (the “Termination Agreement”) with Recordati Ireland, LTD. (“Recordati”), pursuant to which, among other things, the Company and Recordati agreed to terminate that certain License and Supply Agreement, dated September 21, 2020, by and between the Company and Recordati (the “License and Supply Agreement”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ARS Pharmaceuticals, Inc. terminated License and Supply Agreement with Recordati Ireland, LTD. (effective 2023-02-22).

Action: termination
Agreement: license
Counterparty: Recordati Ireland, LTD.
Effective: 2023-02-22

Exact text from the filing

On February 22, 2023, the Company entered into the Termination Agreement with Recordati, pursuant to which, among other things, the Company and Recordati agreed to terminate the License and Supply Agreement, effective immediately.

View on SEC.gov

629 material agreements filed in the last 30 days. Browse all material agreements →

ARS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-044823

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.